316
Participants
Start Date
June 22, 2021
Primary Completion Date
November 30, 2027
Study Completion Date
November 30, 2027
Giredestrant
30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
Abemaciclib
150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
Ipatasertib
400 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
Inavolisib
9 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
Ribociclib
600 mg orally once a day on Days 1-21 of each 28-day cycle until unacceptable toxicity or disease progression
Everolimus
10 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
Samuraciclib
360 mg orally once a day during each 28-day cycle until unacceptable toxicity or disease progression
PH FDC SC
On Day 1 of Cycle 1 (1 cycle is 21 days), pertuzumab and trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) will be administered SC as a fixed dose formulation of 1200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase. On Day 1 of Cycles 2 and beyond, PH FDC SC will be administered SC once every 21 days as a fixed dose of 600 mg pertuzumab, 600 mg trastuzumab, and 20,000 units hyaluronidase.
Palbociclib
125 mg orally once a day on Days 1-21 during each 28-day cycle until unacceptable toxicity or disease progression
Atezolizumab
840 mg by intravenous (IV) infusion on Days 1 and 15 each 28-day cycle.
RECRUITING
Peter Maccallum Cancer Centre, Melbourne
RECRUITING
Peninsula Health-Frankston Hospital, Frankston
RECRUITING
Flinders Medical Centre, Bedford Park
RECRUITING
Linear Clinical Research Limited, Nedlands
RECRUITING
National Cancer Center, Goyang-si
WITHDRAWN
University of Pittsburgh Cancer Institute, Pittsburgh
RECRUITING
Thomas Jefferson University Hospital, Philadelphia
RECRUITING
Hospital Universitario Ramón y Cajal, Madrid
RECRUITING
Centro Integral Oncológico Clara Campal Ensayos Clínicos START, Madrid
RECRUITING
Levine Cancer Institute, Charlotte
RECRUITING
West Cancer Center, Germantown
RECRUITING
Hospital Clinico Universitario de Valencia, Valencia
RECRUITING
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Santa Monica
WITHDRAWN
City of Hope, Duarte
RECRUITING
University of California, San Francisco (UCSF), San Francisco
RECRUITING
Stanford Cancer Institute (SCI), Stanford
RECRUITING
Rabin MC, Petah Tikva
RECRUITING
The Chaim Sheba Medical Center, Ramat Gan
RECRUITING
Tel Aviv Sourasky Medical Center, Tel Aviv
RECRUITING
Hadassah Ein Karem Hospital, Jerusalem
RECRUITING
Massachusetts General Hospital, Boston
WITHDRAWN
Regional Cancer Care Associates LLC (RCCA) - Freehold Location, Freehold
WITHDRAWN
Regional Cancer Care Associates LLC ? Howell Division, Howell Township
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Severance Hospital, Seoul
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Hospital Universitario Vall d Hebron, Barcelona
Hoffmann-La Roche
INDUSTRY